[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"China-Japan Union Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100630100","efficacy-and-safety-of-human-urinary-kallidinogenase-combined-with-reteplase-intravenous-thrombolysis-in-the-treatment-of-acute-ischemic-stroke-100630100",false,"NCT07483281","Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke","KREATE","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023\n2. Age ≥ 18 years\n3. The time from last known well to treatment is within 4.5 hours\n4. First-ever ischemic stroke or have history of ischemic stroke but mRS≤1 before onset\n5. 6 ≤NIHSS≤ 16\n6. Meet the clinical thrombolysis indications in the Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke and receive reteplase intravenous thrombolysis\n7. Have provided signed written informed consent from the patient or the patient's legal representative\n\nExclusion Criteria:\n\n1. Preoperative non-contrast head CT shows Alberta Stroke Program Early CT Score (ASPECTS) ≤ 6\n2. Presence of contraindications to intravenous thrombolysis\n3. Patients who have been on angiotensin-converting enzyme inhibitor (ACEI) drugs and within 5 half-lives (according to the specific drug instructions) before initiate Human Urinary Kallidinogenase treatment\n4. Planed for endovascular treatment\n5. Patients with fracture, claudication and other factors affecting functional outcome score upon admission\n6. Use of Edaravone Injection, Edaravone Dexborneol Injection, Sublingual Edaravone Dexborneol, Butylphthalide Injection or Capsules after the onset of the current episode\n7. Severe uncontrolled hypertension: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg\n8. History of severe food or drug allergies, or prior allergy or intolerance to urinary kallidinogenase for injection\n9. Pregnant or lactating women, or patients planning pregnancy within 90 days\n10. Renal failure or severe renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin) at screening\n11. Liver function impairment: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.5 times the upper limit of normal, or liver diseases (e.g., acute\u002Fchronic hepatitis, cirrhosis)\n12. Heart failure (NYHA Class III or IV), unstable angina, acute myocardial infarction, severe arrhythmia, or second\u002Fthird-degree cardiac conduction obstruction within 6 months before randomization\n13. Drug abuse or addiction in the past year\n14. Concurrent malignant tumors or severe systemic diseases with an expected survival \\\u003C 90 days\n15. Severe mental disorders or dementia unable to complete the informed consent and follow-up\n16. Participation in any interventional drug or device clinical trial within 3 months before screening\n17. Patients deemed unsuitable for the study by the investigator","ALL","18 Years",{"count":19,"type":20},220,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a multicentre, randomized, blinded-endpoint trial that aims to evaluate the efficacy and safety of human urinary kallidinogenase combined with reteplase intravenous thrombolysis in the treatment of acute ischemic stroke",[26],"Acute Ischemic Stroke",[26,28,29,30,31,32],"Human Urinary Kallidinogenase","KLK","Reteplase","HUK","Intravenous Thrombolysis","NOT_YET_RECRUITING","2026-03-25",{"date":36,"type":37},"2026-03-30","ACTUAL",{"date":39,"type":20},"2026-05-01",{"date":41,"type":20},"2028-06-18",{"name":43,"class":44},"China-Japan Union Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100616623","phase-4-clinical-study-on-the-treatment-of-rhinitis-sicca-with-sodium-hyaluronate-adjustable-nasal-irrigator-100616623","NCT07308015","Clinical Study on the Treatment of Rhinitis Sicca With Sodium Hyaluronate Adjustable Nasal Irrigator","Inclusion Criteria:\n\n* Symptoms: Dry nose sensation, little and thick nasal discharge, nosebleeds, itchy nasal cavity, and dryness in the nasopharynx. Physical signs: Nasal endoscopy often reveals dry and congested nasal mucosa, which appears grayish-white or dark red, losing its normal luster. There are often dry, thick secretions, scabs or blood scabs on it. The surface of the nasal mucosa is eroded and ulcers occur. The mucosal lesions are most obvious in the anterior part of the nasal cavity. A diagnosis can be made if one or more of the above symptoms and signs are present.\n\nExclusion Criteria:\n\n1. Those with dry rhinitis and chronic inflammation of the lower respiratory tract.\n2. Those confirmed by examination to be caused by certain latent lesions in the mouth, nose, throat, esophagu.s, neck or the whole body\n3. Those who have used drugs for treating dry rhinitis or other medications within the past 30 days.\n4. Pregnant or lactating women.\n5. Those who are allergic to this medicine.\n6. Those with severe cardiovascular, liver, kidney and hematopoietic system diseases, etc.\n7. Mentally ill patients.","75 Years",{"count":54,"type":20},200,[56],"PHASE4","To observe the therapeutic effect of sodium hyaluronate adjustable nasal irrigator on various types of rhinitis sicca and compare it with the therapeutic effect of the commonly used physiological seawater nasal spray in clinical practice.",[59],"Rhinitis Sicca","RECRUITING","2025-12-15",{"date":63,"type":37},"2025-12-29",{"date":65,"type":37},"2025-06-16",{"date":67,"type":20},"2026-06-12",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":52,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100615570","phase-4-a-prospective-randomized-controlled-study-comparing-the-efficacy-of-intranasal-corticosteroids-incs-combined-with-intranasal-antihistamines-inah-and-incs-combined-with-oral-antihistamines-oah-in-the-treatment-of-moderate-to-severe-allergic-rhinitis-symptoms-100615570","NCT07294326","A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms","Inclusion Criteria:\n\n1. Age range: 12-75 years old, both male and female are welcome;\n2. The diagnostic criteria for moderate to severe allergic rhinitis refer to the \"Chinese Guidelines for Diagnosis and Treatment of Allergic Rhinitis (2022, revised edition)\", which states: (1) Symptoms: the presence of 2 or more symptoms such as paroxysmal sneezing, watery nasal discharge, nasal itching, and nasal congestion, with symptoms lasting or accumulating for more than 1 hour per day, with symptoms appearing for at least 1 year, a single symptom score (TNSS score standard) of 2 points or more, and a total nasal symptom score (TNSS score standard) of 6 points or more. May be accompanied by eye symptoms, including itching, tearing, redness, and burning sensation. (2) Signs: Pale and edematous nasal mucosa, accompanied by watery nasal secretions (3) Allergen testing: at least one allergen SPT and\u002For serum specific IgE positive, or nasal provocation test positive. (4) Severe or severe symptoms that have a significant impact on quality of life, including (i) sleep disorders, (ii) disruptions to daily activities, leisure, and\u002For exercise, (iii) disruptions to learning or work, (iv) anxiety, depression, or restlessness;\n3. The enrolled patients reside in Northeast China and meet the follow-up requirements, including Hulunbuir City, Xing'an League, Tongliao City, Chifeng City, and Xilingol League in Heilongjiang Province, Jilin Province, Liaoning Province, and Inner Mongolia Autonomous Region;\n4. The subjects voluntarily participated in this study and signed a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients who are allergic to other excipients such as azelastine hydrochloride, fluticasone propionate, or related drugs;\n2. Pregnant women;\n3. Patients with arrhythmia, severe organic heart disease, glaucoma, prostate enlargement, active tuberculosis, malignant tumors, systemic immune diseases, or uncontrolled active infections, such as acute upper respiratory tract infections, who cannot be treated with relevant drugs;\n4. Other patients who are unwilling to cooperate with treatment or unable to cooperate with follow-up due to serious systemic or mental illnesses;\n5. There are certain organic diseases of the nasal cavity, such as benign and malignant tumors of the nasal cavity, chronic sinusitis with nasal polyps, etc;\n6. Age\\\u003C12 years old or\\>75 years old;\n7. Patients who have received allergen specific immunotherapy or biologic therapy within the past 6 months;\n8. Those who cannot tolerate serious systemic or local adverse reactions during relevant examinations or specimen collection;\n9. Researchers believe that patients who cannot be included in the group.","12 Years",{"count":77,"type":20},50,[56],"Through prospective exploration of the efficacy of intranasal corticosteroids (INCS) combined with intranasal antihistamines (INAH) and INCS combined with oral antihistamines (OAH) in treating moderate to severe allergic rhinitis symptoms, this study aims to provide evidence-based medical evidence for the standardized treatment of patients with moderate to severe allergic rhinitis accompanied by typical nasal and ocular symptoms.",[81],"Allergic Rhinitis","2025-12-07",{"date":84,"type":37},"2025-12-19",{"date":86,"type":20},"2026-01-01",{"date":88,"type":20},"2026-11-01",{"name":43,"class":44},""]